News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination Committee appointed for the 2021 Annual General Meeting in PledPharma

October 20, 2020

Stockholm, October 20, 2020. The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 29, 2021. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.

The following members have been appointed by the subsequent shareholders:
Cidro Förvaltning AB: Peter Lindell
Nortal Investments AB: Staffan Persson
Fjärde AP-fonden: Jannis Kitsakis
In total, the Nomination Committee represents approx. 31% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Staffan Persson and Jannis Kitsakis are also independent in relation to Cidro Förvaltning AB, which is the largest shareholder in the company in terms of votes.

The Nomination Committee has elected Peter Lindell as chairman. Håkan Åström, Chairman of PledPharma have been nominated to co-opt to the Nomination Committee.

PledPharma AB (publ) signed an agreement to acquire all outstanding shares in Rare Thyroid Therapeutics International AB (RTT) on October 5, 2020. The transaction is expected to be completed on November 3, 2020.

As a part of the share purchase price the former shareholders in RTT will receive 63,773,345 new shares in PledPharma trough an issue of Consideration Shares.

On the occasion of the acquisition of RTT, PledPharma carries out a rights issue of a maximum of 38,238,085 shares. The subscription period is 9 November to 23 November 2020.

The composition of the three largest shareholders will be amended due to the issue of the Consideration shares and the Rights Issue. Therefore, the composition of the future Nomination Committee will also change to reflect the new ownership. PledPharma intends to return with information on the composition of the new Nomination Committee after the new ownership has been registered.

The Committee's assignment is to present proposals regarding Chairman and other members of the, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2022.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email:



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10